Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of SHR-1707 in Healthy Young Adult and Elderly Subjects
NCT04973189Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1707 in Alzheimer's disease (AD), sponsored by Hengrui Therapeutics. Primary endpoint: Incidence and Severity of Adverse Events at 12 weeks. Started May 2021; status: completed.
02
Drugs
SHR-1707
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04973189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973189.